14 Patients with type 2 diabetes who were prescribed semaglutide (either oral or subcutaneous) or lixisenatide were compared to unexposed matched patients
[49] In a phase III double-blind, randomized, controlled trial supported by Eli Lilly, nondiabetic adults with a body mass index of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, were randomized to receive once-weekly, subcutaneous tirzepatide (5, 10, or 15 mg) or placebo
409, Dec
Sleep disturbances in pregnancy
In clinical trials, researchers have examined outcomes related to retatrutide and nad+ therapy combination and found that individual responses vary significantly based on factors like baseline health, dosage, duration of treatment, and concurrent medications